Site icon pharmaceutical daily

Pulmonary Arterial Hypertension Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pulmonary
Arterial Hypertension – Pipeline Review, H1 2019”
drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Pulmonary Arterial Hypertension – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also
reviews of key players involved in therapeutic development for Pulmonary
Arterial Hypertension and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase
I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1,
11, 14, 14, 1, 38, 5 and 1 respectively. Similarly, the Universities
portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules,
respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

Reasons to buy:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/szgfgr/pulmonary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs

Exit mobile version